title: Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients.
abstract: Posttransplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoid diseases that occur after solid organ and bone marrow transplantation. We performed a retrospective study to assess the incidence, response to treatment, and patient and graft survival after PTLD.
  
  
  METHODS
  Between January 1980 and December 2002, 1.96% (n=10) of 509 renal transplant recipients developed PTLD. Seventy percent were men. Mean age was 40 years (range 21-65). They were classified into four groups based upon the type of PTLD: group I, early lesion (n=1); group II, polymorphic PTLD (n=1); group III, monomorphic PTLD (n=7) including five non-Hodgkin lymphoma [NHL] and two Burkitt (BL); and group IV, Hodgkin lymphoma (HL) (n=1). The mean time from transplantation to diagnosis was 77 months (range 4-138). Although only 20% of cases were early presentation, Epstein-Barr virus (EBV) was found in the tumor cells of seven cases. Treatment was individualized according to PTLD type: for group I, immunosuppression reduction (IR); group II, IR plus acyclovir; group III, withdrawal or IR plus chemotherapy and/or surgery in all but one patient who was also treated with anti-CD20 monoclonal antibody and radiotherapy. Interferon was also used in one patient. For group IV, treatment was IR plus radiotherapy.
  
  
  RESULTS
  A complete response was achieved in nine cases (90%) with one recurrence. Three patients returned to dialysis. One patient with BL died.
  
  
  CONCLUSIONS
  The incidence of PTLD in our center was 1.96%. Patient survival after PTLD was 90%, with 60% maintaining allograft function. Individualized treatment according to extension, histology, and location is mandatory to obtain a high survival rate.
authors.affiliation: Department of Nephrology, Hospital del Mar of Barcelona, Barcelona, Spain. 92844@inmas.imim.es
authors.forename: M J
authors.initials: MJ
authors.lastname: Soler
authors.forename: J M
authors.initials: JM
authors.lastname: Puig
authors.forename: M
authors.initials: M
authors.lastname: Mir
authors.forename: J
authors.initials: J
authors.lastname: Parrilla
authors.forename: C
authors.initials: C
authors.lastname: Pedro
authors.forename: A
authors.initials: A
authors.lastname: Salar
authors.forename: S
authors.initials: S
authors.lastname: Serrano
authors.forename: J
authors.initials: J
authors.lastname: Lloveras
mesh_terms: D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D008232:Lymphoproliferative Disorders / Q000145:classification / Q000453:epidemiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents